NCT02419495 2025-06-04
Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies
M.D. Anderson Cancer Center
Phase 1 Terminated
M.D. Anderson Cancer Center
Nektar Therapeutics
Eli Lilly and Company
Eli Lilly and Company
Eli Lilly and Company